Methotrexate May Reduce Risk of Vascular Disease

APRIL 01, 2005
Susan Farley

Investigators at the University of Miami found that methotrexate, commonly used to treat psoriasis and rheumatoid arthritis (RA), may have a secondary function of reducing the risk of atherosclerosis and circulatory diseases that affect the heart and brain. Dr. Robert S. Kirsner explained that methotrexate is an analogue of folate and has anti-inflammatory effects that may reduce vascular disease, while at the same time it is linked to higher levels of homocysteine, which increases the risk of vascular disease. To determine how these effects balance each other out, researchers studied data from 7615 patients with psoriasis and 6707 patients with RA treated at Veterans Administration hospitals in Florida and Puerto Rico. The psoriasis patients who took methotrexate showed a significant reduction in vascular disease risk, but with the lowest risk in those patients given the lowest dose. Similar results were seen in the arthritis patients. Although methotrexate has a poor effect on homocysteine levels, investigators concluded that drug therapy including methotrexate "may provide further vasculoprotective benefits."

Ms. Farley is a freelance medical writer based in Wakefield, RI.



SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.